Free Trial

Day One Biopharmaceuticals (DAWN) Short Interest Ratio & Short Volume

Day One Biopharmaceuticals logo
$7.14 +0.20 (+2.81%)
As of 12:33 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Day One Biopharmaceuticals Short Interest Data

Day One Biopharmaceuticals (DAWN) has a short interest of 11.69 million shares, representing 15.66% of the float (the number of shares available for trading by the public). This marks a -7.30% decrease in short interest from the previous month. The short interest ratio (days to cover) is 8.6, indicating that it would take 8.6 days of the average trading volume of 1.26 million shares to cover all short positions.

Current Short Interest
11,690,000 shares
Previous Short Interest
12,610,000 shares
Change Vs. Previous Month
-7.30%
Dollar Volume Sold Short
$75.99 million
Short Interest Ratio
8.6 Days to Cover
Last Record Date
June 30, 2025
Outstanding Shares
101,360,000 shares
Float Size
74,660,000 shares
Short Percent of Float
15.66%
Today's Trading Volume
470,408 shares
Average Trading Volume
1,263,158 shares
Today's Volume Vs. Average
37%
Short Selling Day One Biopharmaceuticals?
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook

Sign up to receive the latest short interest report for Day One Biopharmaceuticals and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

DAWN Short Interest Over Time

DAWN Days to Cover Over Time

DAWN Percentage of Float Shorted Over Time

Day One Biopharmaceuticals Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
6/30/202511,690,000 shares $75.99 million -7.3%15.7%8.6 $6.50
6/15/202512,610,000 shares $84.11 million -32.1%16.9%10 $6.67
5/31/202518,560,000 shares $118.60 million +0.8%24.9%14.5 $6.39
5/15/202518,420,000 shares $113.47 million +4.1%24.7%13.2 $6.16
4/30/202517,700,000 shares $137.71 million -2.8%23.8%14 $7.78
4/15/202518,200,000 shares $130.86 million +4.1%24.5%15.7 $7.19
3/31/202517,480,000 shares $138.62 million +2.7%23.5%14.6 $7.93
3/15/202517,020,000 shares $138.20 million -6.4%22.9%14.5 $8.12
2/28/202518,180,000 shares $164.71 million +3.9%24.5%15.5 $9.06
2/15/202517,500,000 shares $214.55 million +1.2%23.7%17.5 $12.26
1/31/202517,290,000 shares $213.88 million +4.2%23.8%16.5 $12.37
1/15/202516,600,000 shares $197.04 million -10.5%22.9%14.7 $11.87
12/31/202418,550,000 shares $235.03 million +2.5%25.5%17.5 $12.67
12/15/202418,100,000 shares $230.78 million -7.1%24.9%16.6 $12.75
11/30/202419,490,000 shares $271.50 million +4.5%28.5%17.9 $13.93
11/15/202418,660,000 shares $248.36 million +3.6%27.3%17.6 $13.31
10/31/202418,020,000 shares $265.25 million +12.8%26.4%17.7 $14.72
10/15/202415,980,000 shares $236.98 million +2.0%26.9%16 $14.83
9/30/202415,670,000 shares $218.28 million +3.8%26.4%16 $13.93
9/15/202415,100,000 shares $213.36 million +7.2%25.5%15.4 $14.13
8/31/202414,080,000 shares $194.87 million +3.8%23.8%14.4 $13.84
8/15/202413,570,000 shares $193.10 million +11.1%22.9%13.6 $14.23
7/31/202412,210,000 shares $174.73 million +6.0%20.1%12.5 $14.31
7/15/202411,520,000 shares $180.86 million +10.3%19.0%9.8 $15.70
6/30/202410,440,000 shares $143.86 million +1.5%17.2%8.9 $13.78
6/15/202410,290,000 shares $129.76 million -3.5%17.0%9 $12.61
5/31/202410,660,000 shares $141.46 million +0.6%17.6%9.5 $13.27
5/15/202410,600,000 shares $174.05 million -5.3%17.5%9.7 $16.42
4/30/202411,190,000 shares $191.35 million +25.2%18.5%10.7 $17.10
4/15/20248,940,000 shares $123.82 million -0.5%15.2%10.6 $13.85
3/31/20248,980,000 shares $148.35 million -6.6%15.2%14.5 $16.52
3/15/20249,610,000 shares $138.29 million -0.9%16.3%16.6 $14.39
2/29/20249,700,000 shares $162.28 million -0.2%16.5%17.3 $16.73
2/15/20249,720,000 shares $149.30 million +6.2%16.6%19.5 $15.36
1/31/20249,150,000 shares $137.71 million -15.3%15.5%17.4 $15.05
1/15/202410,800,000 shares $150.55 million +0.5%19.1%16.7 $13.94
12/31/202310,750,000 shares $156.95 million -2.3%19.0%15.1 $14.60
12/15/202311,000,000 shares $156.86 million +2.3%19.4%14.8 $14.26
11/30/202310,750,000 shares $124.49 million -0.7%19.0%13 $11.58
11/15/202310,830,000 shares $130.72 million -8.5%19.2%13.1 $12.07
Trump’s $100 Trillion Land Rush Is On (Ad)

What Is "The US: IPO"? You won't hear this on CNBC... but the government may soon open up hundreds of trillions in oil, gas, lithium, and land rights. Whitney Tilson breaks it all down, and shows how everyday Americans can grab a stake. His urgent new briefing explains "The US: IPO"... and how to get in before the looming federal deadline.

Click here now to discover the full story and how to stake your claim before this land rush goes ful
10/31/202311,840,000 shares $140.07 million +4.3%21.0%14.1 $11.83
10/15/202311,350,000 shares $125.64 million -7.8%20.1%14.7 $11.07
9/30/202312,310,000 shares $151.04 million -0.5%21.3%16.7 $12.27
9/15/202312,370,000 shares $172.19 million +2.7%21.4%16 $13.92
8/31/202312,050,000 shares $162.55 million -0.2%20.4%13.2 $13.49
8/15/202312,070,000 shares $166.32 million -12.4%20.4%10.3 $13.78
7/31/202313,780,000 shares $182.45 million +1.0%30.1%11.5 $13.24
7/15/202313,640,000 shares $158.91 million -2.4%29.8%10.7 $11.65
6/30/202313,980,000 shares $166.92 million +3.5%30.6%11 $11.94
6/15/202313,510,000 shares $177.52 million +35.1%29.6%10.1 $13.14
5/31/202310,000,000 shares $133 million +7.2%21.5%8.8 $13.30
5/15/20239,330,000 shares $129.50 million +2.3%20.1%11.3 $13.88
4/30/20239,120,000 shares $113.09 million +16.0%20.0%11.7 $12.40
4/15/20237,860,000 shares $96.99 million +6.1%17.3%11.6 $12.34
3/31/20237,410,000 shares $99.07 million +11.3%16.3%10.7 $13.37
3/15/20236,660,000 shares $124.34 million +12.1%14.6%12.1 $18.67
2/28/20235,940,000 shares $109.41 million +4.4%13.0%10.7 $18.42
2/15/20235,690,000 shares $111.18 million +6.6%12.5%10.7 $19.54
1/31/20235,340,000 shares $116.25 million -4.5%11.6%10.1 $21.77
1/15/20235,590,000 shares $127.62 million +25.1%14.0%10.5 $22.83
12/30/20224,470,000 shares $96.19 million +3.5%11.2%8.4 $21.52
12/15/20224,320,000 shares $92.53 million -1.1%11.0%8.6 $21.42
11/30/20224,370,000 shares $92.78 million -4.2%11.1%7.3 $21.23
11/15/20224,560,000 shares $99.82 million -9.5%11.6%7.5 $21.89
10/31/20225,040,000 shares $106.55 million -7.9%12.7%7.7 $21.14
10/15/20225,470,000 shares $114.21 million -8.5%14.6%8.5 $20.88
9/30/20225,980,000 shares $119.78 million -3.1%17.0%9.5 $20.03
9/15/20226,170,000 shares $140.55 million -9.3%17.5%9 $22.78
8/31/20226,800,000 shares $159.73 million -6.7%21.3%4 $23.49
8/15/20227,290,000 shares $182.25 million -0.7%22.9%4.2 $25.00
7/31/20227,340,000 shares $125.73 million -6.0%24.3%4.4 $17.13
7/15/20227,810,000 shares $149.48 million +8.2%25.8%4.8 $19.14
6/30/20227,220,000 shares $129.24 million +0.6%23.2%4.5 $17.90
6/15/20227,180,000 shares $109.50 million +37.3%28.1%4.8 $15.25
5/31/20225,230,000 shares $32.53 million +9.2%23.8%17.8 $6.22
5/15/20224,790,000 shares $36.64 million +11.1%21.8%21.1 $7.65
4/30/20224,310,000 shares $36.72 million +6.4%19.8%20.2 $8.52
4/15/20224,050,000 shares $45.85 million +2.3%18.6%18.6 $11.32
3/31/20223,960,000 shares $39.28 million +0.5%N/A16.7 $9.92
3/15/20223,940,000 shares $41.29 million -1.3%18.1%16.1 $10.48
2/28/20223,990,000 shares $54.50 million +0.8%18.4%15.1 $13.66
2/15/20223,960,000 shares $54.61 million +4.8%18.2%14.6 $13.79
1/31/20223,780,000 shares $55.76 million +11.2%17.2%15.3 $14.75
1/15/20223,400,000 shares $47.91 million -1.2%N/A15.3 $14.09
12/31/20213,440,000 shares $57.96 million +30.3%14.8%18.7 $16.85
12/15/20212,640,000 shares $48.18 million +38.2%11.4%16 $18.25
11/30/20211,910,000 shares $35.09 million +6.1%8.8%16.2 $18.37
11/15/20211,800,000 shares $38.27 million -3.7%8.6%19.1 $21.26
10/29/20211,870,000 shares $45.70 million +1.6%8.9%17.7 $24.44
10/15/20211,840,000 shares $40.76 million +3.4%8.8%17.1 $22.15
Trump’s $100 Trillion Land Rush Is On (Ad)

What Is "The US: IPO"? You won't hear this on CNBC... but the government may soon open up hundreds of trillions in oil, gas, lithium, and land rights. Whitney Tilson breaks it all down, and shows how everyday Americans can grab a stake. His urgent new briefing explains "The US: IPO"... and how to get in before the looming federal deadline.

Click here now to discover the full story and how to stake your claim before this land rush goes ful
9/30/20211,780,000 shares $42.24 million +6.6%8.5%16.2 $23.73
9/15/20211,670,000 shares $41.63 million +7.7%8.0%14.9 $24.93
8/31/20211,550,000 shares $43.14 million +22.1%7.8%19 $27.83
8/13/20211,270,000 shares $31.17 million No Change6.4%8.8 $24.54

DAWN Short Interest - Frequently Asked Questions

What is Day One Biopharmaceuticals' current short interest?

Short interest is the volume of Day One Biopharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of June 30th, investors have sold 11,690,000 shares of DAWN short. 15.66% of Day One Biopharmaceuticals' shares are currently sold short. Learn More on Day One Biopharmaceuticals' current short interest.

What is a good short interest ratio for Day One Biopharmaceuticals?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. DAWN shares currently have a short interest ratio of 9.0. Learn More on Day One Biopharmaceuticals's short interest ratio.

Which institutional investors are shorting Day One Biopharmaceuticals?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Day One Biopharmaceuticals: Caption Management LLC, and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

What is a good short interest percentage for Day One Biopharmaceuticals?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 15.66% of Day One Biopharmaceuticals' floating shares are currently sold short.

Is Day One Biopharmaceuticals' short interest increasing or decreasing?

Day One Biopharmaceuticals saw a decline in short interest in June. As of June 30th, there was short interest totaling 11,690,000 shares, a decline of 7.3% from the previous total of 12,610,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is Day One Biopharmaceuticals' float size?

Day One Biopharmaceuticals currently has issued a total of 101,360,000 shares. Some of Day One Biopharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Day One Biopharmaceuticals currently has a public float of 74,660,000 shares.

How does Day One Biopharmaceuticals' short interest compare to its competitors?

15.66% of Day One Biopharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Day One Biopharmaceuticals: Ultragenyx Pharmaceutical Inc. (7.63%), Alvotech (1.63%), Amneal Pharmaceuticals, Inc. (4.56%), Mirum Pharmaceuticals, Inc. (15.35%), Catalyst Pharmaceuticals, Inc. (7.48%), Arrowhead Pharmaceuticals, Inc. (9.55%), ImmunityBio, Inc. (37.57%), Organon & Co. (6.15%), Apellis Pharmaceuticals, Inc. (22.25%), Xenon Pharmaceuticals Inc. (5.92%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($72.10 billion), Invesco QQQ ($26.89 billion), iShares Russell 2000 ETF ($19.61 billion), MicroStrategy Incorporated ($9.52 billion), iShares 20+ Year Treasury Bond ETF ($8.70 billion), WD-40 Company ($7.66 billion), Technology Select Sector SPDR Fund ($6.10 billion), Invesco S&P 500 Equal Weight ETF ($5.80 billion), Invesco S&P 500 Top 50 ETF ($5.53 billion), and Vanguard Large-Cap ETF ($5.35 billion). View all of the most shorted stocks.

What does it mean to sell short Day One Biopharmaceuticals stock?

Short selling DAWN is an investing strategy that aims to generate trading profit from Day One Biopharmaceuticals as its price is falling. DAWN shares are trading up $0.37 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Day One Biopharmaceuticals?

A short squeeze for Day One Biopharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of DAWN, which in turn drives the price of the stock up even further.

How often is Day One Biopharmaceuticals' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including DAWN, twice per month. The most recent reporting period available is June, 30 2025.




This page (NASDAQ:DAWN) was last updated on 7/24/2025 by MarketBeat.com Staff
From Our Partners